Journal
INTERNAL MEDICINE
Volume 61, Issue 10, Pages 1485-1490Publisher
JAPAN SOC INTERNAL MEDICINE
DOI: 10.2169/internalmedicine.7911-21
Keywords
immune checkpoint inhibitor; immune-related adverse event; pancreatitis; colitis
Categories
Ask authors/readers for more resources
Immune checkpoint inhibitors (ICIs) have anti-tumor effects but can also result in a variety of immune-related adverse events (irAEs). This rare case report describes a patient with renal cell carcinoma who developed acute pancreatitis and colitis simultaneously as irAEs during nivolumab treatment, and showed significant improvement with corticosteroid therapy.
Immune checkpoint inhibitors (ICIs), which have anti-tumor effects, are currently approved for treatment of several kinds of advanced malignancies. However, with their increasing use, a variety of immune-related adverse events (irAEs) in administered patients have been reported. We herein report a rare case of the simultaneous onset of acute pancreatitis and colitis as irAEs during nivolumab treatment given to a patient with renal cell carcinoma, who then shown marked improvement with corticosteroid therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available